Controlling how many cells make a fly
- Pete Moore
© BioMed Central Ltd 2003
Published: 21 August 2003
Skip to main content
© BioMed Central Ltd 2003
Published: 21 August 2003
Studies in Drosophila have revealed the Forkhead-family transcription factor FOXO to be a crucial mediator of the branch of the insulin-signaling pathway that controls cell number.
"We know most of the biochemistry of the system from mammalian cell-culture experiments and knockout mice," explains Martin Jünger, a PhD student in Hafen's lab. Decades of experiments have shown that insulin regulates energy metabolism, and more recent results show that it plays a key role in embryonic  and post-embryonic  growth, as well as the determination of lifespan .
Studies in mammalian cells have also shown that insulin negatively regulates FOXO (Forkhead box, subclass O) transcription factors, which in turn arrest the cell cycle and, in some types of cell, induce cell death. FOXO transcription factors therefore have a negative influence on growth, and their function is turned off by the insulin effector protein kinase B (PKB, which is also known as AKT ).
Terms for equivalent proteins in different species
Forkhead transcription factors
Three different hFOXO proteins
Insulin effector kinases, containing pleckstrin homology (PH) domains
PDK1 and PKB/AKT 1–3
PDK1, Akt-1 and Akt-2
dPDK1 and dPKB/dAktfs
The evidence that dauer formation is dependent on the transcription factor DAF-16 comes from genetic experiments showing that if the insulin-signaling pathway is mutated, C. elegans enters the dauer stage. But in a double mutant in which DAF-16 is also disabled, the worms develop as normal. The clear implication is that in normal animals the insulin pathway has its effects on dauer formation via negative regulation of DAF-16. "But the link to growth [in worms] is not clear," says Hafen. "Because this strange worm is built by a precisely fixed number of cells, there is no relation between body size and insulin signaling." This apparent difference in action threw into question the idea that the insulin pathway has a conserved role in worms and mammals.
Into this arena of confusion comes Drosophila. The clearest indication of the way that insulin signaling affects this species comes from the so-called chico mutant. Wild-type Chico protein functions in the insulin-signaling pathway, and flies lacking it are small with delayed development. In many ways this is similar to the situation in mammals, where mutations in the insulin/IGF pathway affect growth and body size. The flies have fewer cells, and the cells they do have are smaller in size. "This [growth] reduction is something that was never seen in C. elegans," says Hafen. "So, before our recent work, the best concept was that the initial pathway was the same in all species, but the readout was different," leading to growth in mammals but preventing dauer formation in C. elegans.
One part of the answer to this question – dealing with the size of each cell – came from a paper previously published in Science . This showed that cell size is controlled in Drosophila by the S6 kinase (dS6K), an enzyme that apparently acts downstream of dPDK1 and dPKB and is named for its effects on ribosomal protein S6. Mutating dS6K produces small flies that have the same number of cells as in the wild type but whose cells are small. The answer to the cell number question came from the paper by Jünger et al. , which initially set out to characterize the fly DAF-16 homolog and to assess both whether and how it fitted into the fly insulin-signaling pathway and also its growth-modulating capabilities.
When the Zürich team produced dFOXO mutants they were initially surprised. The flies were viable and normal-sized; there was no apparent phenotype, other than that the flies were more susceptible to oxidative stress than were their wild-type cousins. Jünger and colleagues had anticipated that removing the presumed negative influence would cause the flies to grow bigger. At first, they questioned whether they really had mutated dFOXO, but the genetic and molecular evidence was compelling.
As a next step, Jünger started to test the mutants in a genetic background in which other aspects of the insulin pathway were compromised. In this case, a normal fly would produce fewer, smaller cells. But take dFOXO away and the flies have small cells, but almost the normal number. "The reduced cell number [in insulin-pathway mutants] is rescued by the absence of the transcription factor, because [wild-type] dFOXO has a negative influence," he explains.
Jünger went on to show that dFOXO operates in part by up-regulating the gene for a binding protein called d4E-BP. With larger quantities of this binding protein produced, the translation-initiation factor eIF4E is effectively removed from the translation machinery, in turn inhibiting the initiation of protein synthesis. This shows that insulin operates not only by regulating pre-existing 4E-BP protein via phosphorylation , but also by influencing the intracellular abundance of 4E-BP at the gene expression level.
"We have shown that d4E-BP is a relevant target [of the pathway]," says Jünger, "but we absolutely don't postulate that it is the only one. It's more like a 'proof-of-principle' experiment, showing that we can find physiologically relevant targets in our rather artificial cell culture system, where we stimulate Drosophila cultured cells with bovine insulin! But recent microarray studies (by Puig et al.  and Ramaswamy et al. ) suggest that FOXO proteins work by modulating the transcription of large sets of target genes."
The picture that emerges for Drosophila is that the insulin signaling pathway forks at PKB, with an S6K element controlling cell size, and a FOXO element taking charge of cell number (see Figure 1).
At the same time as the Jünger et al. paper  was published, two other groups were publishing findings that support the same idea. Robert Tjian and colleagues at the University of California, Berkeley, presented biochemical evidence that when insulin is applied, dFOXO is phosphorylated by dPKB, leading to it being retained in the cytoplasm and therefore not being capable of initiating transcription . His group reports that "targeted expression of dFOXO in fly tissues regulates organ size by specifying cell number with no effect on cell size". Moreover, they also found and validated d4E-BP as a target gene. This nicely complements the findings of Jünger et al. .
On top of this, Tjian's group had another striking result. "We found that FOXO also regulates expression of the insulin receptor," says Tjian. "This means that in the absence of insulin, FOXO is produced. This not only limits growth, but it also up-regulates sensitivity for insulin. The system is now primed to look for lower concentrations of insulin."
A third study, by Jamie Kramer and colleagues at the Memorial University of Newfoundland, Canada, presents a slightly different picture. Kramer et al.  agree with Jünger et al. and Tjian's group that dFOXO is the fly homolog of DAF-16 and hFOXO (see Table 1). But, in a key difference, Kramer et al. found that overexpression of dFOXO leads to reductions in both cell size and cell number. "We have seen this effect in both the eye and the wing of Drosophila," says Kramer. He believes that this difference between his results and those of the other groups is most likely to arrive from his use of overexpression analysis whereas Jünger used loss-of-function techniques.
"A general problem," agrees Jünger, "is that overexpression studies are prone to artefacts, because overexpressed proteins often start doing things which under normal, physiological protein concentrations they do not." Tjian agrees; "If I got results from overexpression experiments that differ from loss-of-function work I would be inclined to trust the loss-of-function study," he says. At the same time, Tjian points out that his team's findings also came from overexpression studies. He is now keen to study the exact differences in method between his own and Kramer's work to see if this sheds light on the differences.
For Hafen, the new data complete the triangle. "In the worm, fly and human, FOXO is [a] negative [regulator of growth]," he says. "Now the pictures do not look different at all. What we see is a great underlying evolutionary conservation of this pathway." In Hafen's view, this pathway governs one of the most fundamental controls that the ancestors of multicellular organisms had to evolve. "Wild flies are not like our laboratory flies, fed on delicious food day in, day out. In nature animals often have too little food, so they have to evolve mechanisms to deal with the issue. They can't just run their metabolism at maximal speed, irrespective of whether there is food around or not; they have to find ways to adjust their metabolic rate and their speed of development according to the availability of nutrients."
He postulates that his group didn't see the full effect of the dFOXO mutants because the flies were growing in unnatural conditions: because the flies are fed the whole time, the insulin pathway is constantly activated. A constantly starving wild fly with a dFOXO mutation might have an impaired ability to limit its rate of growth to suit the nutrient availability.
Hafen likens the situation to driving a car when you know that the tank is running out of fuel. "You don't go at hundred and forty kilometers an hour, you reduce speed to reduce fuel consumption," he comments. "This is what animals had to learn to do during evolution – and they do it at least in part via the insulin-IGF pathway. The main goal of this pathway is to adjust growth rates, or the developmental program in the case of C. elegans, with respect to availability of food, and the mechanism is conserved right down to the level of the DAF-16 transcription factor."
Tjian is also excited by the findings. "We are starting to get a better idea of how transcription factors affect organ size and how they are used to decide when to stop putting new cells into organs," he says. And understanding the role that FOXO plays in morphogenesis has far-reaching implications in both the laboratory and medical practice.